Semaglutide (sold as Ozempic, Wegovy and Rybelsus) was initially developed to treat diabetes
Oral semaglutide is the first GLP-1RA available in a tablet form, and therefore could be important in facilitating treatment intensification with GLP-1RAs and providing an alternative option for patients with a preference for oral glucose-lowering therapy to achieve better glycemic control
Neither is distilled water from the grocery store
In a large study published in the New England Journal of Medicine, Semaglutide (which is the active ingredient in both Ozempic) led to an average weight loss of about 15% of the body weight in about a year, which is an average total weight loss of about 33.7 lbs
Reasons for low levels of initiation and long-term use of AOMs may include reluctance of public health and medical organizations to recognize obesity as a disease, lack of reimbursement, provider inexperience, and misperceptions about the efficacy and safety of available treatments
Semaglutide, the active ingredient in drugs like Ozempic and Wegovy , produces an average weight loss of 15% over the course of a year and a half